Discussion: Previous modeling and simulation studies showed contradicting results for
N501Y mutant on ACE2 recognition.
Discussion: Recent data suggest that
N501Y mutation does not significantly alter the binding affinity with Bamlanivimab.
Discussion: recently evaluated the susceptibility